5 unknown, 3 recruiting, 1 completed, 1 terminated. 10 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Unknown 5, Recruiting 3, Completed 1, Terminated 1 |
| Phase 1 | 7 | Unknown 5, Recruiting 2 |
Follow Non-hodgkin Lymphoma,B Cell: new trials by email Literature Review of Non-hodgkin Lymphoma,B Cell trials Research Report on Non-hodgkin Lymphoma,B Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL Allogenic CD19-CAR-γδT cell, Fludarabine, Cyclophosphamide - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2025-07-27 | 2025-07-30 |
| CAR T-cell Therapy in Patients With Renal Dysfunction Fludarabine, Cyclophosphamide - Non-hodgkin Lymphoma,B Cell, Multiple Myeloma | Phase 2 | Recruiting | Northside Hospital, Inc. | 20 | 2024-11-18 | 2026-10-14 |
| Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL Allogeneic CD19-STAR T cell, Fludarabine, Cyclophosphamide - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 30 | 2024-03-20 | 2024-03-25 |
| TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 38 | 2023-06-30 | 2023-07-06 |
| Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma Azacytidine, Bendamustine and Piamprizumab - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2021-04-22 | 2021-05-21 |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma Allogeneic CD19 CR-T cell - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-03 |
| Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Acalabrutinib - Non-hodgkin Lymphoma,B Cell | Phase 2 | Completed | Seoul National University Hospital | 66 | 2019-07-09 | 2023-04-18 |
| PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma MT-3724, Gemcitabine, Oxaliplatin - Non-hodgkin Lymphoma,B Cell, Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | Molecular Templates, Inc. | 8 | 2018-08-20 | 2022-08-16 |
| Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 TriCAR-T-CD19 - Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Timmune Biotech Inc. | 6 | 2018-08-03 | 2019-09-06 |
| CART-19 Immunotherapy in Mantle Cell Lymphoma anti-CD19-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Non-hodgkin Lymphoma,B Cell | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 2 | 2014-03-01 | 2014-03-11 |
Hematologic Neoplasms (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma (3) · Hematologic Diseases (2) · Lymphoma, Non-Hodgkin (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Disease Attributes (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1)
Cyclophosphamide (4) · fludarabine (4) · Injections (3) · fludarabine phosphate (3) · Azacitidine (1) · Bendamustine Hydrochloride (1) · Gemcitabine (1) · Lenalidomide (1) · Oxaliplatin (1) · Rituximab (1) · acalabrutinib (1)
Chinese PLA General Hospital (5) · Molecular Templates, Inc. (1) · Northside Hospital, Inc. (1) · Seoul National University Hospital (1) · Shenzhen University General Hospital (1) · Timmune Biotech Inc. (1)
China (7) · United States (2) · South Korea (1)
Li Yu, Dr (1) · Ming Zhou (1) · Weidong Han, Ph.D (1)